Biliary Tract Cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Biliary Tract Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Biliary Tract Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Biliary Tract Cancer: Overview
Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.
'Biliary Tract Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Biliary Tract Cancer pipeline landscape is provided which includes the disease overview and Biliary Tract Cancer treatment guidelines. The assessment part of the report embraces, in depth Biliary Tract Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Biliary Tract Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Biliary Tract Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Biliary Tract Cancer Emerging Drugs
Further product details are provided in the report……..
Biliary Tract Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Biliary Tract Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Biliary Tract Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Biliary Tract Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Biliary Tract Cancer drugs.
Biliary Tract Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Biliary Tract Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Biliary Tract Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Biliary Tract Cancer: Overview
Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.
'Biliary Tract Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Biliary Tract Cancer pipeline landscape is provided which includes the disease overview and Biliary Tract Cancer treatment guidelines. The assessment part of the report embraces, in depth Biliary Tract Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Biliary Tract Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Tract Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Biliary Tract Cancer.
This segment of the Biliary Tract Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Biliary Tract Cancer Emerging Drugs
- Pembrolizumab: Merck & Co.
- Disitamab vedotin: RemeGen
Further product details are provided in the report……..
Biliary Tract Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Biliary Tract Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Biliary Tract Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Biliary Tract Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Biliary Tract Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Biliary Tract Cancer drugs.
Biliary Tract Cancer Report Insights
- Biliary Tract Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Biliary Tract Cancer drugs?
- How many Biliary Tract Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Biliary Tract Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Biliary Tract Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Biliary Tract Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck
- RemeGen
- EMD Serono
- SMT bio Co., Ltd.
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Jiangsu HengRui Medicine Co., Ltd.
- InnoPharmax Inc.
- Lee's Pharmaceutical Limited
- Hoffmann-La Roche
- Eisai
- TerSera Therapeutics LLC
- Shanghai Miracogen Inc.
- Zymeworks Inc.
- Mirati Therapeutics
- BeiGene
- Bristol-Myers Squibb
- Eli Lilly and Company
- Ipsen
- Threshold Pharmaceuticals
- Leap Therapeutics
- Hutchison Medipharma Limited
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Daiichi Sankyo
- 3D Medicines
- RaND Biosciences
- Incyte Corporation
- Sotio a.s.
- Carisma Therapeutics Inc
- Senhwa Biosciences, Inc.
- Seagen
- Bolt Biotherapeutics, Inc.
- Black Diamond Therapeutics, Inc.
- Redx Pharma Plc
- Silverback Therapeutics
- Taiho Oncology, Inc.
- Zai Lab (Shanghai) Co., Ltd.
- Pembrolizumab
- Disitamab vedotin
- Bintrafusp alfa
- SMT-NK
- HA121-28
- SHR1258
- D07001
- ZKAB001
- Atezolizumab
- Lenvatinib
- telotristat ethyl
- MRG003
- ZW25
- Sitravatinib
- Tislelizumab
- Nivolumab
- Ramucirumab
- Nanoliposomal Irinotecan
- TH-302
- DKN-01
- Surufatinib
- TQB2450
- Trastuzumab deruxtecan
- Envafolimab
- SC-43
- INCB001158
- SO-C101
- CT-0508
- CX-4945
- Tucatinib
- BDC-1001
- BDTX-189
- RXC004
- SBT6050
- TAS0728
- Niraparib
Introduction
Executive Summary
Biliary Tract Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Pembrolizumab: Merck & Co.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Disitamab vedotin: RemeGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
RO7119929: Hoffmann-La Roche
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Biliary Tract Cancer Key Companies
Biliary Tract Cancer Key Products
Biliary Tract Cancer- Unmet Needs
Biliary Tract Cancer- Market Drivers and Barriers
Biliary Tract Cancer- Future Perspectives and Conclusion
Biliary Tract Cancer Analyst Views
Biliary Tract Cancer Key Companies
Appendix
Executive Summary
Biliary Tract Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Pembrolizumab: Merck & Co.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Disitamab vedotin: RemeGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
RO7119929: Hoffmann-La Roche
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Biliary Tract Cancer Key Companies
Biliary Tract Cancer Key Products
Biliary Tract Cancer- Unmet Needs
Biliary Tract Cancer- Market Drivers and Barriers
Biliary Tract Cancer- Future Perspectives and Conclusion
Biliary Tract Cancer Analyst Views
Biliary Tract Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Biliary Tract Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Biliary Tract Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Biliary Tract Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Biliary Tract Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
